Oncogenic KRAS engages an RSK1/NF1 pathway to inhibit wild-type RAS signaling in pancreatic cancer.
Cheng DK, Oni TE, Thalappillil JS, Park Y, Ting HC, Alagesan B, Prasad NV, Addison K, Rivera KD, Pappin DJ, Van Aelst L, Tuveson DA.
Cheng DK, et al.
Proc Natl Acad Sci U S A. 2021 May 25;118(21):e2016904118. doi: 10.1073/pnas.2016904118.
Proc Natl Acad Sci U S A. 2021.
PMID: 34021083
Free PMC article.